SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR

CHEBI:CHEBI_752032

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
1939335
product_type
HUMAN PRESCRIPTION DRUG
marketing_category
NDA
listing_expiration_date
20251231
route
ORAL
active_ingredient_strength
400 mg/1
dosage_form
TABLET, FILM COATED
pharm_class_moa
HCV NS3/4A Protease Inhibitors [MoA]
pharm_class
HCV NS3/4A Protease Inhibitors [MoA]
nui
N0000182638
active_ingredient_name
VOXILAPREVIR
unii
0570F37359
pharm_class_epc
Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]
labeler_name
Gilead Sciences, Inc.
manufacturer_name
Gilead Sciences, Inc.
marketing_start_date
20170718
package_marketing_start_date
20170718
generic_name
SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR
brand_name
Vosevi
brand_name_base
Vosevi
product_ndc
61958-2401
application_number
NDA209195
spl_id
965dff7b-aaeb-4025-bce1-75c541beeb0a
package_ndc
61958-2401-1
package_description
28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-2401-1)
spl_set_id
17ffc094-8ca7-45d2-80d8-fd043bc9a221
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class